BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Status:
Recruiting
Trial end date:
2023-12-20
Target enrollment:
Participant gender:
Summary
This is a phase 2, single arm, open label, adaptive design study to determine the preliminary
anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV)
pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma that
have progressed on anti-PD-1-containing treatment.